The Slovak COVID-19 vaccine is a step forward, the first antibodies have been tested on live viruses

Biotech firm Axon Neuroscience successfully tested the first therapeutic antibodies to live SARS-Cov-2 virus in a clinical trial.

During the development of the COVIDAX vaccine against the infectious disease COVID-19, the company, according to published information, has managed to develop antibodies that can effectively prevent the multiplication of the SARS-CoV-2 virus.

The antibodies, which have proven their effectiveness in several independent tests, have been able to document the vulnerabilities of the virus that are accessible to the immune system.

Lightening of the health system

According to Michal Fresser, CEO of Axon, the concept is based on independent research. Thanks to this, it was possible to identify antibodies that can have a therapeutic effect in patients with COVID-19. In addition to the COVIDAX vaccine, the company’s ambition is to bring drugs to the market that can stop or alleviate the COVID-19 infectious disease.

“This would significantly relieve the health system, which is the area most severely affected by the pandemic,” Michal Fresser added, saying they opened the project to investors with the aim of building Slovak science independently of political pressure and multinational corporations.

The antibody test is performed at the Virology Institute of the Biomedical Center of the Slovak Academy of Sciences, where the efficacy of selected candidate antibodies is tested directly on live SARS-CoV-2 virus, which is propagated in cell cultures.

The antibodies were effective against the virus

The results of these tests showed that the antibodies were able to effectively prevent the virus from interacting with the host cell and thus prevent it from multiplying.

Axon Neuroscience is a biotechnology company and a pioneer in the development of peptide vaccines against previously incurable brain diseases.

The company was founded in 1999 and today has the largest team exclusively specializing in the development of peptide vaccines against Alzheimer’s disease in the world. Axon’s vaccine, AADvac1, is the most clinically advanced vaccine under development for the treatment and prevention of Alzheimer’s disease.

More on the topic: Coronavirus